Name | Dapoxetine hydrochloride |
Description | Dapoxetine hydrochloride (LY-210448 hydrochloride) is a selectivity short-acting serotonin reuptake inhibitor, used for the therapy of premature ejaculation. |
Kinase Assay | PKA enzyme activity: cAMP-dependent protein kinase activity is assayed in a reaction mixture containing, in a final volume of 0.2 mL, 50 mM Tris-HC1 (pH 7.0), 10 mM magnesium acetate, 2 mM EGTA, 1 μM cAMP or absence of cAMP, 3.3-20 μM [γ-32P]ATP (4 × 105 cpm), 0.5 μg of the enzyme, 100 μg of histone H2B, and each compound, as indicated. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | H2O : 25.6 mg/mL (74.88 mM), Sonication is recommended. DMSO : 50 mg/mL (146.25 mM), Sonication is recommended.
|
Keywords | sexual disorder | SerotoninTransporter | Serotonin Transporter | serotonin reuptake | Prostate Hyperplasia | Premature ejaculation | LY210448 Hydrochloride | LY210448 | LY 210448 Hydrochloride | LY 210448 | Dapoxetine | BPH | Benign | 5HTReceptor | 5HT Receptor | 5-HT |
Inhibitors Related | Serotonin hydrochloride | Alverine citrate | Olanzapine | Clozapine N-Oxide | Mirtazapine | D-Menthol | Amitriptyline hydrochloride | Cloperastine hydrochloride | Trazodone hydrochloride | Mianserin hydrochloride | Fluoxetine hydrochloride | Cinchonidine |
Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |